HLB Pep Co., Ltd. (KOSDAQ:196300)

Market Cap	43.60B -50.6%
Revenue (ttm)	5.52B +14.6%
Net Income	-2.07B
EPS	-874.70
Shares Out	9.38M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,484
Open	5,200.00
Previous Close	5,040.00
Day's Range	4,685.00 - 5,200.00
52-Week Range	4,685.00 - 9,990.00
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About HLB Pep

HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection; and AGM-290 indicated for the treatment of infections ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 196300

Financial Performance

In 2025, HLB Pep's revenue was 4.96 billion, a decrease of -20.34% compared to the previous year's 6.23 billion. Losses were -642.47 million, -90.54% less than in 2024.